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Abstract
Radiotherapy continues to be a major treatment for solid tumours and is a cornerstone of modern
oncology. The term 'radiation oncology' describes the integration of radiation therapy into the
complexity of multi-modal therapy. Over the last ten years the crucial role of radiation therapy as
part of multi-modality protocols in cancer care has been documented in numerous Phase III trials.
Advances in treatment technology as well as the underlying biology of tumour resistance
mechanisms will further strengthen the role of radiation oncology. The scientific role of radiation
oncology is reflected by the increase in the number of papers related to radiation oncology in
resources like Medline. In order to reflect the growing scientific importance of radiation oncology,
radiation physics and radiation biology, we have initiated Radiation Oncology as the first open access
journal in the field. Open access allows for a rapid and transparent publication process together
with an unequalled opportunity to reach the widest reader spectrum possible.
Introduction
It is predicted that in 2006 there will be 1.25 million non-
skin cancers diagnosed in North America, and 75% of
these patients will receive radiotherapy sometime during
the course of their disease. Although there has been much
success in terms of local tumour control using radiother-
apy there has been less success in terms of an improve-
ment in overall survival in patients receiving only
radiotherapy. Future successes using radiotherapy will
hinge on the proper integration of clinical radiotherapy,
radiation biology and radiation physics into general treat-
ment approaches and the application of these findings in
a timely fashion. We are convinced that research in the
areas introduced in more detail in the following para-
graph will improve the understanding of how radiation
acts on tumours and ultimately change the clinical prac-
tice.
Hot topics in radiation oncology
Generally, several distinct hot topic areas may be distin-
guished. In the field of radiation biology we believe that
cell death research aiming to dissect the pathways under-
lying radiation-induced inactivation of clonogenic tumor
cell death is of crucial importance [1]. In addition, many
lines of evidence point to the fact that molecular changes
introduced by hypoxia and the micromilieu will impact
on the efficacy of radiation treatments [2]. Furthermore,
radiation sensitivity is controlled by a wide array of
growth factors, cytokines, adhesion molecules derived
from the tumour stroma or the malignant cell itself. All of
these factors are clearly targets for therapeutic intervention
[3].
In order to individually tailor a treatment approach it is of
crucial importance to define sets of molecules relevant for
the prediction of clinical responses. In this regard, it seems
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likely that complex expression patterns rather than single
molecules will guide clinical decisions [4,5]. Since thera-
peutic gain is the result after balancing tumour cell kill
against normal tissue damage, research regarding the
molecular and cellular mechanisms of side effects has the
potential to positively influence radiation oncology.
Independently from radiation biology, radiation technol-
ogy in combination with new imaging modalities will
strongly improve outcomes. In this regard, the introduc-
tion of intensity modulated radiotherapy (IMRT) based
on the results of functional imaging studies (PET, MRI)
will definitively change our daily radiation practice,
although many problems still have to be solved [6].
Although the use of charged particles has high potential
impact [7], it remains speculative in how far these modal-
ities will change the daily treatment practice in a near
future as the costs of such treatments are extremely high
and access to dedicated treatment facilities is limited.
In order to establish a platform for a rapid and virtually
unlimited distribution of new results from any of the
fields mentioned above we have chosen to initiate the
open access journal Radiation Oncology.
Open access
Open access has three broad benefits for science, medicine
and the general public.
First, authors are assured that their work is disseminated
to the widest possible audience: all articles are archived in
several freely accessible archives, such as PubMed Central
(USA), the open repositories at the University of Potsdam
(Germany), within INIST (France), and within e-Depot
(Netherlands).
Second, the information available to readers will not be
limited by their library's budget as all articles are freely
and universally accessible online at no cost to the reader.
Third, the results of publicly funded research will be acces-
sible to all taxpayers and not just those with proper library
access as the authors hold copyright of their work and
grant anyone the right to reproduce and disseminate the
article.
In addition, the review process, considered to be of crucial
importance for scientific quality, is available to the whole
scientific community as soon as the paper is published
(every paper will be published alongside its prepublica-
tion history). Furthermore, for reasons of clarity and fair-
ness the reviewers do not remain anonymous. We are
convinced that both features help keep the whole review
process as transparent as possible.
Submission policy
Manuscripts are submitted to Radiation Oncology using the
online submission system [8]. Submitted manuscripts
will be handled by the Editor-in-chief or assigned to a
member of our Editorial Board [9], who will seek critical
reviews of the manuscript. Once accepted, articles will be
published online immediately and will be listed in
PubMed soon after.
We look forward to receiving your submissions.
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